Table 3.
Clinicopathological data of patients with SARS-CoV-2 infection.
| Normal range | Moderate patients (n = 38) | Severe patients (n = 25) | P-value | |
|---|---|---|---|---|
| Laboratory findings (Mean±SD) | ||||
| O2 saturation (Spo2) | – | 93.20 ± 4.46 | 86.23 ± 7.87 | < 0.001 |
| WBC × 109 (U/L) | 4.5–10.5 × 109 | 7.75 ± 3.96 | 9.04 ± 3.69 | 0.223 |
| Lymphocyte × 109 (U/L) | 1.32–3.57 × 109 | 2.358 ± 9.29 | 1.540 ± 7.77 | 0.011 |
| PLT × 109 (U/L) | 150–400 × 109 | 187.05 ± 90.11 | 252.50 ± 82.65 | 0.115 |
| ALT (U/L) | 0–41 | 40.12 ± 36.21 | 85.75 ± 18.39 | 0.252 |
| AST (U/L) | 0–40 | 40.67 ± 32.66 | 74.88 ± 12.20 | 0.209 |
| Hb (g/ml) | 13–17.5 | 10.78 ± 2.63 | 11.28 ± 2.94 | 0.509 |
| LDH (U/L) | <248 | 513.16 ± 140.81 | 1107.12 ± 751.69 | 0.03 |
| ESR (mm/h) | 0–15 | 47.20 ± 37.01 | 26.43 ± 20.76 | 0.76 |
| D-dimer (mg/L) | 0–500 | 928.33 ± 1056.59 | 2270.81 ± 3541.12 | 0.01 |
| CRP (mg/L) | >10 | 31.83 ± 32.38 | 43.44 ± 39.72 | 0.247 |
| Comorbidity | ||||
| Chronic pulmonary diseases | 0% (0 of 38) | 12% (3 of 25) | 0.029 | |
| Diabetes | 12.43% (7 of 38) | 24% (6 of 25) | 0.241 | |
| Hypertension | 21% (8 of 38) | 32% (8 of 25) | 0.329 | |
| Cardiovascular diseases | 15.8% (6 of 38) | 28% (7 of 25) | 0.592 | |
| Chronic kidney diseases | 10.5% (4 of 38) | 8% (2 of 25) | 0.156 | |
| Cancers | 7.9% (3 of 38) | 16% (4 of 25) | 0.865 | |
| Metastatic Adenocarcinoma | 1 of 38 | 2 of 25 | – | |
| Lymphoma | 1 of 38 | 1 of 25 | – | |
| Hepatoblastoma | 1 of 38 | 1 of 25 | – |